Every material Form 8-K Eledon Pharmaceuticals, Inc. has filed with the SEC since March 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eledon Pharmaceuticals reported a second-quarter 2026 net loss of $31.6 million, or $0.27 per share, compared with $11.2 million, or $0.13 per share, a year earlier. The loss was driven largely by a $9.6 million non-cash charge from changes in warrant liabilities; excluding that item, the net loss was $22.0 million versus $23.5 million. Cash and short-term investments fell to $88.8 million, which the company expects to fund operations into the second quarter of 2027.
Q2 2026 net loss $31.6 million ($0.27 per share) vs. $11.2 million ($0.13 per share) in Q2 2025
Non-cash warrant liability loss of $9.6 million in Q2 2026 vs. a $12.3 million gain in Q2 2025
Excluding warrant items, net loss was $22.0 million vs. $23.5 million
Cash, cash equivalents and short-term investments were $88.8 million at June 30, 2026, funding operations into Q2 2027
Eledon Pharmaceuticals reported a first quarter 2026 net loss of $39.0 million, or $0.33 per share, up from $6.5 million, or $0.08 per share, a year earlier. The loss was driven mainly by a $19.0 million non-cash charge from changes in the fair value of warrant liabilities, and cash, cash equivalents and short-term investments fell to $111.1 million, which the company says will fund operations into 2Q 2027.
Net loss was $39.0 million for the quarter ended March 31, 2026, versus $6.5 million a year earlier, including a $19.0 million non-cash warrant fair value loss compared with a $10.1 million gain in 2025.
Excluding warrant fair value changes, the net loss was $20.1 million, compared with $16.6 million in the first quarter of 2025.
Research and development expenses rose to $17.2 million from $13.5 million, while general and administrative expenses fell to $4.0 million from $4.4 million.
Cash and short-term investments totaled $111.1 million at March 31, 2026, down from $133.3 million at December 31, 2025.
Eledon Pharmaceuticals reported its fourth quarter and full year 2025 results on March 19, 2026. The net loss for 2025 widened to $45.6 million from $36.2 million, driven by higher research and development expenses, though the loss per share narrowed to $0.52 from $0.66 on a larger share count.
Full-year 2025 net loss was $45.6 million, or $0.52 per basic share, versus $36.2 million, or $0.66 per share, in 2024.
Research and development expenses rose to $66.3 million from $52.0 million, which the company attributed to clinical trial activity, manufacturing scale-up and added personnel.
A non-cash gain of $33.4 million from changes in the fair value of warrant liabilities reduced the 2025 net loss; excluding warrant items, the net loss would have been $79.1 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Eledon Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →